300171.SHE Shanghai Tofflon Science Tech
- Market cap
- CNY 10.4B
- P/E
- 38.6x
- P/B
- 1.30x
- ROE
- 3.3%
- Dividend yield
- 0.79%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300171.SHE undervalued?
Graham number300171.SHE trades 49.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Tofflon Science Tech fundamental analysis
No fundamental analysis for Shanghai Tofflon Science Tech yet.
Shanghai Tofflon Science Tech stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Tofflon Science Tech
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. The company offers technological research, including cell technology, complex preparation, injection, and OSD laboratory; instruments comprising cell therapy and nucleic acid drugs instruments, laboratory facilities, and table reactor; single use technology that include bioreactors, liquid distribution …
Full company profileShanghai Tofflon Science Tech financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Tofflon Science Tech annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.33B | 1.72B | 1.92B | 2.26B | 2.71B | 4.19B | 5.47B | 5.64B | 5.01B | 5.23B | 4.82B |
| Gross Profit | 554M | 596M | 570M | 725M | 1.10B | 1.90B | 2.09B | 1.89B | 1.30B | 1.54B | 1.63B |
| Operating Income | 262M | 166M | 113M | 187M | 549M | 1.02B | 999M | 703M | 216M | 325M | 510M |
| EBITDA | 251M | 192M | 95.1M | 195M | 512M | 981M | 926M | 678M | 207M | 420M | 357M |
| Net Income | 235M | 123M | 70.5M | 146M | 463M | 828M | 847M | 600M | 194M | 200M | 261M |
| EPS | 0.37 | 0.20 | 0.11 | 0.23 | 0.74 | 1.30 | 1.33 | 0.79 | 0.26 | 0.26 | 0.34 |
| Balance Sheet | |||||||||||
| Total Assets | 4.20B | 4.37B | 4.69B | 5.21B | 6.58B | 9.74B | 13.4B | 12.9B | 13.1B | 13.5B | 14.0B |
| Total Liabilities | 1.20B | 1.28B | 1.57B | 1.97B | 2.89B | 5.26B | 5.73B | 4.79B | 5.02B | 5.34B | 5.73B |
| Shareholders' Equity | 2.92B | 2.99B | 3.03B | 3.15B | 3.60B | 4.32B | 7.44B | 7.88B | 7.81B | 7.93B | 8.01B |
| Cash & Short-term Investments | 889M | 783M | 566M | 2.12B | 3.10B | 3.82B | 4.99B | 2.83B | 2.96B | 3.12B | 2.92B |
| Total Debt | 5.00M | 65.6M | 12.3M | 2.93M | 3.10M | 8.23M | 5.59M | 3.87M | 9.79M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 107M | 20.9M | 222M | 446M | 1.12B | 1.37B | 247M | -312M | 881M | 731M | - |
| Capital Expenditure | 9.18M | 36.5M | 32.0M | 14.0M | 26.7M | 454M | 726M | 695M | 499M | 271M | 111M |
| Free Cash Flow | 98.2M | -15.6M | 190M | 432M | 1.09B | 915M | -479M | -1.02B | 382M | 460M | 349M |
| Ratios | |||||||||||
| ROE | 8.0% | 4.1% | 2.3% | 4.6% | 12.9% | 19.2% | 11.4% | 7.6% | 2.5% | 2.5% | 3.3% |
| ROA | 5.6% | 2.8% | 1.5% | 2.8% | 7.0% | 8.5% | 6.3% | 4.7% | 1.5% | 1.5% | 1.9% |
| Net Profit Margin | 17.7% | 7.1% | 3.7% | 6.4% | 17.1% | 19.7% | 15.5% | 10.6% | 3.9% | 3.8% | 5.4% |
| Debt to Equity | 0.00x | 0.02x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Tofflon Science Tech dividends
- Dividend yield
- 0.79%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 40.9%
- Ex-dividend date
- Sep 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 82.0M | 0.11 | 40.9% |
| 2024 | CNY 182M | 0.24 | 93.9% |
| 2023 | CNY 249M | 0.33 | 41.5% |
| 2022 | CNY 245M | 0.38 | 28.9% |
| 2021 | CNY 138M | 0.22 | 16.7% |
| 2020 | CNY 44.0M | 0.07 | 9.5% |
| 2019 | CNY 25.1M | 0.04 | 17.2% |
| 2018 | CNY 15.0M | 0.02 | 21.3% |
| 2017 | CNY 159M | 0.26 | 129.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jun 19, 2015.
Who owns Shanghai Tofflon Science Tech
- Insiders 53.03%
- Institutions 11.52%
- Public & others 35.46%
- Shares outstanding 766M
- Free float 364M
Shanghai Tofflon Science Tech company profile
- Company name
- Shanghai Tofflon Science Tech
- Ticker
- 300171.SHE
- ISIN
- CNE100000ZP0
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Feb 1, 2011
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,479
- Fiscal year end
- December
- Address
- Building 4, Shanghai, China, 201108
- Phone
- 86 21 6490 9699
- Website
- tofflon.com
About Shanghai Tofflon Science Tech
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. The company offers technological research, including cell technology, complex preparation, injection, and OSD laboratory; instruments comprising cell therapy and nucleic acid drugs instruments, laboratory facilities, and table reactor; single use technology that include bioreactors, liquid distribution systems, sterile bags, process chromatography, membrane filtration systems, and others; and cryopreservation system for seeds and biological samples, as well as freeze-thaw system of biological stock solutions. It also provides culture medium, such as cell and gene therapy, biomacromolecule drugs, tobitec feeding medium, and other series; bioreactors, fermentation systems, cell factory, perfusion, and complementary systems; preparation systems, including bio-process vessel and piping, common solutions preparation, and complex injectable formulation systems; and separation and purification systems comprising disc centrifuge, membrane filtration, chromatography system and columns, alkali lysis, slurry tank, and filters. In addition, the company offers resins, API, cleaning and sterilization, filling line, and OSD products and services. Further, it provides freeze-drying systems that include laboratory, production, and special application freeze-drying products, as well as loading and unloading system; packaging systems, such as packaging solutions, cartoner machine, top-load cartoner machines, blister machine, solid bottling equipment, labelling machine, and case packer with palletizer machines; isolator and inspection systems; and engineering services. The company was formerly known as Shanghai Tofflon Science and Technology Co., Ltd. Tofflon Science and Technology Group Co., Ltd. was founded in 1993 and is headquartered in Shanghai, China.
Shanghai Tofflon Science Tech management
8- Mr. Xiaodong ZhengChairman & GM · born 1964
- Mr. Dehua LuFinancial Director · born 1981
- Mr. Jin Wang ZhengTechnology Director & Director · born 1976
- Mr. Jianlin YaoDeputy GM & Director · born 1977
- Ms. Yan WangDeputy GM & Secretary of the Board of Directors · born 1979
- Mr. Jinsheng ChengDeputy General Manager · born 1981
- Mr. Guoxing ZhaoR & D Director · born 1979
- Zhao WeiAccounting Supervisor